Company · Healthtech & Bio

CONNECTA Therapeutics

connectatherapeutics.com ↗ ·Barcelona ·Seed

Barcelona-based clinical-stage biotech developing novel treatments for central nervous system (CNS) disorders with unmet medical needs, spun off from Prous Institute for Biomedical Research in 2019. Lead asset CTH120 is a first-in-class neuroplasticity modulator being developed for fragile X syndrome and other neurodevelopmental conditions; the company reported positive Phase I results and began Phase IIa trials in 2026, backed by a €2.5M EIC Accelerator grant.

Founded

2019

Founders

News

Rounds

Investors

SectorsHealthtech & Bio, Biotechnology, CNS/Neuroscience, Drug Discovery Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Profile updated 3 Aug 2026

Founders

Jordi Fàbrega

Co-Founder, CEO & Board Member

Josep Prous Jr.

Co-Founder, CSO & Board Member

Global models

No comparables on record yet.

Investors 4

Prous Institute for Biomedical Research

www.prousresearch.com ↗

Investor Spain

Funding rounds 2

Series A · €3.1M

The Barcelona Science Park biotech raised €3.1M led by new investor Clave Capital through its Innvierte Science Tech Clave Innohealth fund, …

2026-09-10

Other · €2.7M

A public-private consortium formed by CONNECTA Therapeutics, the CRG, the Hospital del Mar Research Institute and I3PT was awarded €2.7 mill…

2024-02-12

News & media 12

Published	Article
2026-09-14	Radar de rondas: Harvey y Mistral, las grandes protagonistas de la semana ↗ Forbes España
2026-09-10	La biotecnològica Connecta Therapeutics tanca una ronda de 3,1 milions ↗ VIA Empresa
2026-09-10	CONNECTA Therapeutics levanta 3,1 millones de euros ↗ El Referente
2026-09-10	CONNECTA Therapeutics levanta 3,1 millones para el desarrollo clínico de CTH120 para el síndrome X Frágil ↗ Infosalus (Europa Press)
2026-09-10	CONNECTA Therapeutics (síndrome X Frágil) atrae €3,1M en ronda liderada por Clave. Participa Inveready, CDTI y Prous Institute ↗ Webcapitalriesgo
2026-09-10	CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program ↗ GlobeNewswire (press release)
2026-06-10	CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome ↗ GlobeNewswire
2025-10-08	A Fresh Approach: CONNECTA Therapeutics & Fragile X Syndrome ↗ National Fragile X Foundation
2025-09-09	CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support ↗ PR Newswire (via Yahoo Finance)
2025-05-06	Jordi Fàbrega, CEO of Connecta Therapeutics: "The PCB is a hub of excellence in biosciences, where research and development thrive, and that's why we feel so aligned with it" ↗ Parc Científic de Barcelona
2025-03-04	CONNECTA Therapeutics announces positive results from Phase I study of neurodevelopmental disorders drug candidate, CTH120 ↗ Parc Científic de Barcelona
2024-02-12	CONNECTA Therapeutics, a Prous Institute spin-off, CRG, Hospital del Mar Research Institute and I3PT receive €2.7 million from the Spanish Ministry of Science and Innovation to begin Phase IIa trials for CTH120 in Fragile X syndrome ↗ Prous Institute for Biomedical Research